conjug
deconjug
ubiquitin
ub
ubiquitinlik
protein
ubl
cellular
protein
multifacet
univers
mean
regul
cellular
physiolog
control
lifetim
local
activ
mani
critic
protein
deconjug
ub
ubl
protein
perform
class
proteas
call
isopeptidas
herein
describ
readili
quantifi
novel
isopeptidas
assay
platform
consist
ub
ubl
fuse
report
enzym
phospholipas
pla
isopeptidas
activ
releas
pla
cleav
substrat
gener
signal
linear
deubiquitylas
dub
concentr
abl
discrimin
dub
desumoylas
deneddylas
deisgylas
activ
power
sensit
ublpla
assay
demonstr
abil
differenti
contrast
deisgylas
dub
activ
two
coronaviru
proteas
sever
acut
respiratori
syndrom
papainlik
proteas
sarscov
plpro
cov
papainlik
proteas
furthermor
direct
comparison
current
ubamc
assay
demonstr
ubpla
assay
effect
tool
character
modul
isopeptidas
activ
observ
expand
profil
inhibitori
activ
nonselect
isopeptidas
inhibitor
nsc
dub
desumoylas
taken
togeth
studi
illustr
util
reporterbas
approach
measur
isopeptidas
activ
supplement
materi
see
wwwproteinscienceorg
content
protein
cell
govern
ubiquitinproteasom
pathway
hershko
ciechanov
ubiquitin
ub
ubiquitinlik
protein
ubl
sumo
regul
protein
addit
mechan
exampl
intracellular
compartment
signal
transduct
regul
ligas
welchman
et
al
degrad
target
protein
ubiquitin
system
typic
involv
concert
action
two
three
enzym
review
see
hershko
ciechanov
typic
polyubiquityl
polypeptid
deliv
proteasom
complex
hydrolyz
polypeptid
short
oligopeptid
releas
free
ubiquitin
recycl
process
revers
ubiquitin
well
ubl
deconjug
proteas
call
ubiquitin
ubl
isopeptidas
term
isopeptidas
herein
refer
proteas
specif
cleav
ubiquitin
ubl
termin
carboxyl
group
ubiquitin
ubl
amerik
hochstrass
deubiquitylas
dub
isopeptidas
cleav
carboxyl
terminu
ubiquitin
divid
five
distinct
group
largest
ubiquitinspecif
proteas
uspubp
amerik
hochstrass
nijman
et
al
approv
proteasom
inhibitor
bortezomib
velcad
multipl
myeloma
valid
ubiquitin
proteasom
pathway
cancer
treatment
bross
et
al
unfortun
toxic
associ
proteasom
inhibit
limit
clinic
applic
bortezomib
proteasom
inhibitor
contrast
therapeut
strategi
target
specif
aspect
ubiquitinproteasom
pathway
predict
better
toler
genom
identifi
least
human
gene
put
encod
enzym
involv
conjug
deconjug
ubiquitin
least
thought
encod
function
dub
multipl
isoform
wong
et
al
nijman
et
al
consider
progress
made
studi
ubiquitin
conjug
howev
studi
dub
still
nascent
stage
import
aberr
dub
activ
carcinogenesi
recent
review
nicholson
et
al
addit
dub
multipl
famili
ublspecif
isopeptidas
exist
cleav
sumo
cleav
ganerden
et
al
cheng
et
al
mous
homolog
human
isopeptidas
origin
report
deisgylas
dub
activ
mice
character
prematur
death
brain
cell
injuri
elev
level
conjug
brain
ritchi
et
al
howev
relev
deisgylas
activ
question
follow
observ
phenotyp
mice
rescu
addit
knockout
knobeloch
et
al
coronaviru
sever
acut
respiratori
syndrom
papainlik
proteas
sarscov
plpro
report
dub
deisgylas
activ
harcourt
et
al
barretto
et
al
lindner
et
al
use
fluorogen
report
ubamc
recent
report
sar
cov
plpro
function
preferenti
deisgylas
lindner
et
al
anoth
report
demonstr
second
coronaviru
encod
isopeptidas
papainlik
proteas
dub
activ
chen
et
al
interestingli
presenc
absenc
deisgyl
activ
report
chen
et
al
medic
relev
illustr
studi
demonstr
associ
upper
lower
respiratori
tract
infect
fouchier
et
al
van
der
hoek
et
al
van
der
hoek
et
al
first
dub
clone
decad
ago
wilkinson
et
al
tobia
varshavski
date
commerci
avail
option
monitor
isopeptidas
activ
highthroughput
screen
ht
manner
ublamc
conjug
lanthascreen
dub
substrat
dang
et
al
ganerden
et
al
lindner
et
al
horton
et
al
given
potenti
drawback
associ
assay
measur
isopeptidas
activ
sought
develop
superior
reporterbas
assay
previous
report
number
dub
abl
cleav
ub
conjug
link
eor
apeptid
linkag
similar
effici
larsen
et
al
lin
et
al
furthermor
select
enzym
requir
free
amino
terminu
catalyt
activ
initi
describ
prototyp
isopeptidas
assay
studi
activ
catalyt
core
yeast
sumo
proteas
arnold
et
al
data
present
herein
describ
gener
report
system
consist
ub
ubl
fuse
amino
terminu
altern
report
phospholipas
pla
apeptid
bond
assay
abl
determin
contrast
substrat
specif
coronaviru
proteas
plpro
character
novel
modul
isopeptidas
activ
demonstr
broad
util
ubpla
assay
base
fact
pla
requir
free
amino
terminu
catalyt
activ
pla
cleav
linkag
ca
depend
reaction
requir
free
amino
terminu
catalyt
activ
fig
dijkstra
et
al
initi
recombin
report
construct
consist
ub
fuse
amino
terminu
mous
solubl
pla
group
x
express
purifi
addit
core
catalyt
domain
isopeptidas
hereaft
refer
overexpress
fusion
protein
escherichia
coli
proof
concept
coupl
assay
provid
observ
abl
cleav
ubpla
complet
follow
incub
room
temperatur
fig
b
furthermor
cleavag
ubpla
dose
depend
detect
liber
fluorophor
nbd
amino
nbd
c
hpc
fig
supplement
fig
initi
lag
cleavag
pla
substrat
nbd
c
hpc
partial
due
coupl
natur
ubpla
assay
determin
fluoresc
readout
assay
accur
reflect
activ
fluoresc
intens
fit
fourthord
polynomi
equat
fig
x
factor
plot
concentr
strong
linear
relationship
reveal
confirm
dose
depend
assay
see
discuss
addit
dub
express
purifi
insect
cell
similar
linear
relationship
observ
nm
incub
nm
ubpla
mm
nbd
c
hpc
supplement
fig
thu
dub
ubpla
assay
use
monitor
dosedepend
dub
activ
ublpla
assay
appli
spectrum
isopeptidas
gaug
util
assay
expand
observ
dub
effect
specif
cleav
ub
pla
test
abil
isopeptidas
cleav
altern
ubl
domain
pla
recombin
fusion
protein
express
purifi
e
coli
addit
isopeptidas
express
purifi
bacteria
insect
cell
examin
rel
isopeptidas
activ
isopeptidas
four
ublpla
report
construct
tabl
expect
primarili
deubiquitin
enzym
consist
publish
report
cleavag
ubpla
significantli
enhanc
incub
presenc
nm
mono
ub
supplement
fig
dang
et
al
reyesturcu
et
al
similarli
mammalian
yeast
desumoylas
core
core
confirm
desumoylas
figur
ubpla
novel
isopeptidas
report
construct
specif
cleavag
isopeptidas
carboxytermin
glycin
ub
releas
catalyt
activ
pla
abl
turn
substrat
liber
fluoresc
product
deneddyl
enzym
deneddylas
sarscov
plpro
core
preferenti
deisgylas
report
previous
plpro
also
dub
activ
howev
equimolar
amount
ubpla
test
concurr
plpro
gener
much
stronger
signal
ubpla
report
barretto
et
al
lindner
et
al
lindner
et
al
interestingli
select
data
suggest
nm
abl
cleav
nm
ubpla
nm
similar
effici
tabl
unabl
determin
km
valu
ub
due
lack
satur
kinet
data
shown
howev
compar
lower
concentr
nm
nm
ublpla
twofold
higher
signal
observ
incub
ubpla
rel
fig
contrast
fluoresc
readout
nm
plpro
greater
rel
ubpla
fig
expect
rel
fluoresc
unit
rfu
valu
enhanc
ubpla
vs
contrast
dub
nm
unabl
cleav
ubpla
ublpla
report
construct
enzym
highli
activ
demonstr
abil
cleav
altern
report
ubamc
supplement
fig
data
consist
observ
ubiquitin
ctermin
hydrolas
preferenti
cleav
ub
small
adduct
exemplifi
ubamc
larsen
et
al
addit
nm
member
machadojoseph
diseas
domain
subfamili
dub
unabl
cleav
nm
ublpla
report
fusion
protein
detect
pla
activ
howev
higher
concentr
cleav
ubpla
supplement
fig
compar
result
seen
ubamc
suggest
rel
weak
dub
exhibit
substrat
specif
supplement
fig
taken
togeth
data
demonstr
ublpla
assay
format
util
tool
dissect
specif
purifi
isopeptidas
ubpla
report
compar
favor
report
system
wish
determin
rel
activ
ublpla
system
comparison
isopeptidas
report
assay
equimolar
concentr
ubpla
ubamc
directli
compar
low
nm
concentr
ubpla
found
produc
significantli
higher
signaltobackground
sb
ratio
concentr
ubamc
supplement
fig
one
applic
isopeptidas
report
discoveri
character
novel
isopeptidas
inhibitor
prior
screen
inhibitor
determin
assay
robust
reproduc
ht
format
design
valu
zhang
et
al
ubpla
assay
exceed
valu
requir
usabl
ht
assay
valu
supplement
tabl
supplement
fig
test
whether
ubpla
report
system
capabl
identifi
inhibitor
ec
valu
wellcharacter
dub
inhibitor
ubiquitin
aldehyd
ubald
determin
use
nm
ubpla
mm
nbd
c
hpc
nm
ubamc
fig
compar
ec
valu
obtain
ubald
mediat
inhibit
measur
ubpla
nbd
c
hpc
nm
ubamc
nm
lanthascreen
dub
substrat
repres
altern
report
system
measur
dub
activ
direct
comparison
reveal
usp
test
core
core
core
core
plpro
core
isopeptidas
activ
determin
three
independ
experi
normal
control
ub
core
core
plpro
mean
sd
present
ubpla
assay
significantli
sensit
supplement
fig
addit
applic
ublpla
assay
platform
includ
measur
isopeptidas
activ
crude
cell
lysat
monitor
partial
fraction
scheme
hela
cell
cell
supplement
fig
b
observ
isopeptidas
activ
inhibit
nonspecif
sulfhydryl
alkyl
agent
nethylmaleimid
nem
confirm
assay
measur
cystein
proteas
activ
supplement
fig
data
shown
data
confirm
ublpla
sensit
report
system
util
measur
activ
crude
cell
lysat
addit
purifi
protein
aleo
colleagu
report
nsc
inhibit
ubiquitin
isopeptidas
illustr
abil
inhibit
zlrggamc
cleavag
crude
lysat
midmicromolar
rang
aleo
et
al
character
nsc
purifi
enzym
determin
inhibitori
potenti
purifi
demonstr
nsc
dub
inhibitor
also
desumoylas
inhibitor
fig
specif
nsc
inhibit
ec
valu
mm
mm
mm
respect
importantli
nsc
inhibit
report
enzym
pla
concentr
rang
test
mm
indic
report
inhibit
select
isopeptidas
fig
expect
nem
inhibit
ec
valu
mm
mm
mm
respect
fig
nem
inhibit
pla
concentr
rang
test
mm
data
shown
ethylenediaminetetraacet
acid
edta
inhibit
ca
depend
pla
enzym
presenc
mm
cacl
ec
valu
mm
fig
gener
ublpla
report
system
base
previous
report
observ
number
dub
abl
cleav
ub
conjug
link
eor
apeptid
linkag
similar
effici
larsen
et
al
lin
et
al
took
advantag
observ
matur
pla
requir
free
amino
terminu
catalyt
activ
creat
fusion
protein
ubl
link
pla
apeptid
bond
fig
dijkstra
et
al
data
show
isopeptidas
assay
configur
format
broad
util
scope
term
ubiquitin
famili
member
efficaci
divers
system
includ
cell
lysat
subsequ
fraction
initi
experi
reveal
cleav
ubpla
liber
nbd
dosedepend
manner
reflect
r
valu
respect
x
factor
polynomi
fit
curv
plot
dub
concentr
fig
supplement
fig
thu
ubpla
fusion
protein
link
apeptid
bond
appropri
monitor
purifi
dub
activ
shape
progress
curv
figur
due
sever
factor
first
lag
fluoresc
appear
due
coupl
natur
assay
complic
fact
substrat
pla
larg
micellar
requir
bulk
transport
monomer
substrat
pla
act
thu
use
polynomi
fit
pure
phenomenolog
appar
relationship
x
factor
enzym
amount
may
aris
fact
e
similar
assay
mean
concentr
es
complex
lead
product
format
determin
fact
subsequ
profil
rel
activ
seven
dub
ubpla
tabl
data
reveal
ubpla
assay
effect
tool
profil
activ
largest
class
dub
usp
like
function
usp
four
five
usp
test
robust
activ
ubpla
neglig
activ
ublpla
conjug
activ
enhanc
presenc
exogen
ub
supplement
fig
consist
known
specif
polyubiquitin
dang
et
al
reyesturcu
et
al
contrast
ubpla
assay
appear
appropri
measur
activ
uch
enzym
ubpla
assay
also
low
activ
member
machadojoseph
diseas
domain
proteas
howev
note
higher
concentr
dosedepend
dub
activ
observ
similar
observ
made
ubamc
supplement
fig
interestingli
rel
poor
vitro
cleavag
ub
conjug
consist
previou
report
anoth
member
machadojoseph
domain
ataxin
mao
et
al
chose
expand
initi
observ
express
purifi
three
addit
ublpla
report
specif
rel
activ
five
isopeptidas
determin
four
ublpla
report
construct
tabl
expect
behav
desumoyl
enzym
deneddylas
consist
previou
vitro
data
preferenti
deisgylas
addit
hand
plpro
deisgylas
tabl
fig
moreov
data
agreement
recent
report
sar
cov
plpro
function
preferenti
deisgylas
lindner
et
al
contrast
nm
relat
coronaviru
proteas
appear
cleav
ub
conjug
equal
well
test
nm
ubpla
nm
followup
experi
demonstr
lower
concentr
nm
abl
gener
significantli
greater
signal
incub
ubpla
rel
suggest
prefer
ub
rel
fig
confirmatori
kinet
experi
uninform
due
lack
substrat
satur
data
shown
recent
catic
colleagu
profil
dub
desumoylas
deisgylas
activ
dub
three
overlap
studi
use
suicid
inhibitor
catic
et
al
interestingli
approach
found
dub
howev
catic
colleagu
report
also
bound
sulfon
suggest
deisgyl
activ
well
dub
activ
contrast
detect
signific
enzymat
deisgyl
activ
tabl
previous
group
describ
abil
bind
sulfon
knowledg
enzymat
cleavag
conjug
demonstr
hemelaar
et
al
report
deisgyl
activ
publish
conflict
highlight
import
profil
isopeptidas
activ
measur
proteolyt
cleavag
activ
addit
substrat
bind
number
dub
assay
report
includ
commerci
avail
ubamc
lanthascreen
dub
substrat
contrast
ubamc
lanthascreen
dub
substrat
ubpla
assay
dub
cleav
protein
c
terminu
ub
like
repres
physiolog
substrat
dub
layfield
et
al
addit
although
ubamc
use
screen
inhibitor
excit
wavelength
uv
rang
known
result
fals
posit
rate
high
ht
liu
et
al
tirat
et
al
importantli
compar
ec
valu
obtain
inhibit
specif
dub
inhibitor
ubald
detect
ubpla
nbd
c
hpc
ubamc
illustr
ubpla
assay
appropri
screen
inhibitor
isopeptidas
fig
util
ubpla
assay
ht
screen
platform
modul
isopeptidas
activ
illustr
assay
exhibit
valu
rang
supplement
tabl
supplement
fig
case
coupl
enzym
assay
possibl
compound
directli
modul
activ
pla
compound
howev
rapidli
elimin
counterscreen
free
pla
fig
taken
togeth
data
demonstr
respect
numer
class
dub
usp
ubpla
assay
ideal
determin
rel
enzym
activ
contrast
ubamc
lanthascreen
dub
substrat
seem
better
suit
uch
famili
dub
evid
util
ublpla
assay
provid
character
previous
report
dub
inhibitor
aleo
et
al
initi
report
nsc
test
purifi
protein
rather
shown
inhibit
cleavag
ub
mimet
zlrggamc
transform
fibroblast
lysat
studi
expand
observ
aleo
colleagu
demonstr
nsc
inhibit
purifi
cleavag
ubpla
fig
b
addit
nsc
inhibit
desumoylas
suggest
compound
rel
nonselect
isopeptidas
inhibitor
fig
moreov
isopeptidas
inhibitori
activ
nsc
confirm
observ
inhibit
free
pla
concentr
rang
test
fig
thu
ublpla
assay
ideal
ht
applic
screen
usp
inhibitor
summari
data
present
within
demonstr
ublpla
report
assay
robust
sensit
assay
exemplifi
plpro
platform
use
discrimin
dub
desumoylas
deisgylas
deneddylas
activ
ublpla
report
system
begin
provid
new
mechanist
insight
field
ubl
isopeptidas
furthermor
addit
report
fusion
consist
altern
report
enzym
requir
free
amino
terminu
activ
fuse
ubl
current
develop
data
shown
isopeptidas
clearli
emerg
diseas
target
propos
ublpla
report
system
extrem
use
tool
identifi
novel
inhibitor
activ
target
usp
nicholson
et
al
estim
datapoint
gener
therapeut
import
isopeptidas
use
current
assay
format
importantli
screen
format
assay
exceed
throughput
data
point
per
day
valu
pubchem
aid
h
veith
auld
per
comm
result
show
assay
robust
data
describ
result
screen
campaign
subject
futur
public
unless
state
otherwis
reagent
obtain
sigma
chemic
compani
minimum
reagent
grade
better
plasmid
encod
purchas
open
biosystem
magicmark
size
marker
nbd
c
hpc
lanthascreen
dub
substrat
procur
invitrogen
ecl
reagent
ubiquitin
aldehyd
procur
biomol
matur
mous
group
x
pla
amino
acid
clone
express
bacteria
novagen
use
standard
molecular
biolog
techniqu
see
supplement
tabl
primer
inform
express
purifi
describ
gasparian
et
al
leach
michael
subsequ
pla
also
subclon
bacteri
express
vector
gener
recombin
respect
express
purif
describ
free
catalyt
activ
pla
gener
incub
overnight
room
temperatur
ensur
complet
cleavag
prior
affin
subtract
ninta
bead
clone
express
purif
bacteria
catalyt
core
fragment
core
amino
acid
core
amino
acid
amino
acid
sarscov
plpro
amino
acid
fulllength
perform
use
standard
molecular
biolog
techniqu
see
supplement
tabl
primer
inform
codonoptim
cdna
amino
acid
prepar
synthet
www
express
purifi
bacteria
fulllength
clone
express
purifi
cell
use
standard
molecular
biolog
techniqu
see
supplement
tabl
primer
inform
isopeptidas
core
express
purifi
describ
larsen
et
al
malakhov
et
al
russel
wilkinson
marbleston
et
al
antiub
sigma
chemic
compani
antirabbithrp
jackson
immunoresearch
laboratori
visual
ecl
reagent
unless
state
otherwis
recombin
isopeptidas
mix
ublpla
nbd
c
hpc
final
concentr
nm
nm
mm
respect
total
volum
ml
well
blackwal
greiner
bioon
dilut
perform
pla
assay
buffer
mm
trishcl
ph
mm
cacl
mm
bmercaptoethanol
unless
state
otherwis
increas
fluoresc
intens
time
determin
perkinelm
envis
fluoresc
plate
reader
excit
emiss
filter
nm
nm
respect
room
temperatur
net
rfu
determin
subtract
blank
rfu
valu
mm
nbd
c
hpc
pla
assay
buffer
data
point
core
ubpla
dose
depend
experi
perform
mix
nm
core
nm
ubpla
mm
nbd
c
hpc
total
volum
ml
data
fit
fourthord
polynomi
equat
bx
cx
dx
ex
use
graphpad
prism
graphpad
softwar
linear
signal
rel
isopeptidas
concentr
determin
perform
linear
regress
x
factor
c
versu
isopeptidas
concentr
rel
isopeptidas
activ
variou
ublpla
fusion
determin
ad
test
isopeptidas
final
concentr
nm
combin
mm
nbd
c
hpc
nm
individu
ublpla
report
construct
ubpla
net
rfu
determin
describ
signal
isopeptidas
report
background
report
ratio
determin
within
linear
rang
assay
min
express
sb
percentag
control
isopeptidas
ubpla
plpro
followup
experi
perform
ad
test
isopeptidas
final
concentr
nm
combin
mm
nbd
c
hpc
nm
ubpla
data
rfu
time
point
use
analysi
ublpla
assay
reagent
avail
lifesensor
inc
wwwlifesensorscom
nm
core
incub
concentr
rang
ubaldehyd
min
supplement
equal
volum
nm
ubpla
mm
nbd
c
hpc
nm
ubamc
biomol
boston
biochem
increas
fluoresc
monitor
time
use
ascent
fluoroskan
use
follow
wavelength
ex
em
ubpla
ex
em
ubamc
rfu
valu
within
initi
linear
rang
normal
report
alon
inhibit
core
report
inhibit
plot
use
graphpad
prism
ec
valu
determin
fit
data
sigmoid
dose
respons
variabl
slope
equat
nm
nm
nm
preincub
concentr
rang
nsc
ncinih
development
therapeut
program
control
min
supplement
equal
volum
nm
ubpla
mm
nbd
c
hpc
nm
mm
nbd
c
hpc
rel
activ
enzym
determin
measur
rfu
valu
singl
time
point
within
initi
linear
rang
usp
min
min
min
rfu
valu
within
initi
linear
rang
normal
isopeptidas
vehicl
inhibit
isopeptidas
nem
inhibit
ec
valu
determin
inhibitori
activ
test
compound
report
enzym
pla
perform
describ
except
preincub
step
data
normal
free
pla
vehicl
inhibit
free
pla
edta
inhibit
pla
activ
determin
min
addit
reagent
supplement
materi
consist
tabl
valu
pcr
primer
figur
illustr
dosedepend
activ
enhanc
activ
presenc
monoub
dosedepend
activ
measur
ubamc
dosedepend
activ
measur
ubpla
ubamc
comparison
ubpla
ubamc
lanthascreen
substrat
data
distribut
util
ublpla
assay
monitor
fraction
wholecel
lysat
